PTC Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
PTC Therapeutics, Inc. (PTCT) reported Finance Lease, Right-of-Use Asset, Amortization of $41.38 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2023-02-21
- PTC Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-09-30 was $170.00K.
- PTC Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $3.71M.
- PTC Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2020 was $41.38M, a 1015.72% increase from fiscal 2019.
- PTC Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2019 was $3.71M.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $170.00K derived: sum of 2 quarters · filed 2023-02-21 | $41.38M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $41.38M 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | $41.21M 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $3.71M 10-K · filed 2020-03-02 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |